← boardnext 2026-12
GLSI
Greenwich LifeSciences, Inc.distress 4/10 · elevated risk$13.06-2%today-61% from 52w high
Lead: Breast Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$11M
Runway
1.0 yrs
Shares 1y
+8%
Price & events
-44.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-31.3%
1W
-43.3%
1M
-44.8%
3M
-48.7%
6M
+13.7%
1Y
-18.6%
2Y
-68.7%
5Y
-62.6%
All
Overview
- Market Cap
- $191.70M
- Volume
- 47.05K
- 52 Week Range
- $7.85 – $33.56
- Total Shares
- 14.68M
- Float Shares
- 7.39M
- Short %
- 19.05%
- % Held by Insiders
- 47.86%
- % Held by Institutions
- 12.48%
- RVOL
- 0.28x
- Beta
- 1.39
Pipeline stages · 1 programs
GLSI-100
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | GLSI-100 | Breast Cancer | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-07-21HC Wainwright & Co.Buy
- 2025-12-30HC Wainwright & Co.Buy
- 2025-04-21HC Wainwright & Co.Buy
- 2025-02-11HC Wainwright & Co.Buy
- 2024-08-23HC Wainwright & Co.Buy
Competitors — Breast Cancer
- NVSEFNOVARTIS AG$292.0B · D3
- GILDGILEAD SCIENCES, INC.$159.5B · D2
- PFEPFIZER INC$142.2B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- RLAYRelay Therapeutics, Inc.$3.6B · D6
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- PRLDPrelude Therapeutics Inc$307M · D6
- OKUROnKure Therapeutics, Inc.$172M · D6
- ATOSATOSSA THERAPEUTICS, INC.$22M · D6
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Greenwich LifeSciences adds up to 10 UK trial sites - grafa.com
- 2026-07-22Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com - Investing.com Nigeria
- 2026-07-22Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial - Quiver Quantitative
- 2026-07-22Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom - GlobeNewswire
- 2026-07-22UK approval could add 5-10 sites to Greenwich LifeSciences trial - Stock Titan
- 2026-07-21Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha
- 2026-07-20Greenwich LifeSciences expands Phase III breast cancer trial - grafa.com
- 2026-07-20Greenwich LifeSciences updates phase III breast cancer trial design By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.